Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Hope S. Rugo, MD"'
Autor:
Rita A. Mukhtar, MD, Michael Holland, MD, David A. Sieber, MD, Kwun Wah Wen, MD, PhD, Hope S. Rugo, MD, Marshall E. Kadin, MD, Gregory R. Bean, MD, PhD
Publikováno v:
Plastic and Reconstructive Surgery, Global Open, Vol 7, Iss 4, p e2188 (2019)
SUMMARY:. A 59-year-old woman with a history of cosmetic implants developed ipsilateral synchronous breast implant–associated anaplastic large cell lymphoma (BIA-ALCL) and invasive ductal carcinoma in the left breast. Each tumor was subjected to ne
Externí odkaz:
https://doaj.org/article/b039f24562884db295787122a1b5cf5c
Autor:
Anand Dhruva MD, Cairn Wu BA, Christine Miaskowski RN, PhD, Wendy Hartogensis Phd, MPH, Hope S Rugo MD, Shelley R Adler PhD, Ted J Kaptchuk, Rucha Kelkar BAMS, PT, DPT, Sangeeta Agarawal RN, MS, CAS, Amisha Vadodaria BA, Ellen Garris CAS, Frederick M Hecht MD
Publikováno v:
Global Advances in Health and Medicine, Vol 9 (2020)
Purpose Ongoing symptoms and impairments in quality of life (QOL) among breast cancer survivors remain a significant problem. We tested the feasibility and acceptability of a manualized Ayurvedic nutrition and lifestyle intervention for breast cancer
Externí odkaz:
https://doaj.org/article/94458066dc3c417f87483585ccb5b091
Autor:
Xiao-ran Liu PhD, Ru-yan Zhang MD, Hao Gong PhD, Hope S. Rugo MD, Ling-bo Chen PhD, Yuan Fu PhD, Jian-wei Che PhD, Jian Tie MD, Bin Shao MD, Feng-ling Wan, Wei-yao Kong MBBS, Guo-hong Song MD, Han-fang Jiang MD, Guo-bing Xu MD, Hui-ping Li MD
Publikováno v:
Technology in Cancer Research & Treatment, Vol 19 (2020)
Background: More than 30% of estrogen receptor-positive breast cancers are resistant to primary hormone therapy, and about 40% that initially respond to hormone therapy eventually acquire resistance. Although the mechanisms of hormone therapy resista
Externí odkaz:
https://doaj.org/article/e592ea94349f454a833b411628097897
Autor:
Rugo HS; Hope S. Rugo, MD, Department of Medicine, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Aditya Bardia, MD, MPH, Medical Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; and Sara M. Tolaney, MD, MPH, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Bardia A; Hope S. Rugo, MD, Department of Medicine, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Aditya Bardia, MD, MPH, Medical Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; and Sara M. Tolaney, MD, MPH, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Tolaney SM; Hope S. Rugo, MD, Department of Medicine, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Aditya Bardia, MD, MPH, Medical Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; and Sara M. Tolaney, MD, MPH, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2023 Mar 10; Vol. 41 (8), pp. 1631-1632. Date of Electronic Publication: 2023 Jan 06.
Autor:
Rugo HS; Hope S. Rugo, MD, University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Gerardo A. Umanzor, MD, Centro Oncológico Integral With DEMEDICA, San Pedro Sula, Honduras; and Min-Fun R. Kwan, MBBS, MRCP, and David L. Cutler, MD, Athenex, Inc, Buffalo, NY., Umanzor GA; Hope S. Rugo, MD, University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Gerardo A. Umanzor, MD, Centro Oncológico Integral With DEMEDICA, San Pedro Sula, Honduras; and Min-Fun R. Kwan, MBBS, MRCP, and David L. Cutler, MD, Athenex, Inc, Buffalo, NY., Kwan MR; Hope S. Rugo, MD, University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Gerardo A. Umanzor, MD, Centro Oncológico Integral With DEMEDICA, San Pedro Sula, Honduras; and Min-Fun R. Kwan, MBBS, MRCP, and David L. Cutler, MD, Athenex, Inc, Buffalo, NY., Cutler DL; Hope S. Rugo, MD, University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Gerardo A. Umanzor, MD, Centro Oncológico Integral With DEMEDICA, San Pedro Sula, Honduras; and Min-Fun R. Kwan, MBBS, MRCP, and David L. Cutler, MD, Athenex, Inc, Buffalo, NY.
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2023 Feb 20; Vol. 41 (6), pp. 1323-1324. Date of Electronic Publication: 2022 Nov 03.